share_log

Truist Securities Maintains Buy on Sutro Biopharma, Raises Price Target to $25

Truist Securities Maintains Buy on Sutro Biopharma, Raises Price Target to $25

Truist Securities 维持买入 Sutro Biopharma,将目标股价上调至
Benzinga Real-time News ·  2023/01/13 08:27

Truist Securities analyst Asthika Goonewardene maintains Sutro Biopharma (NASDAQ:STRO) with a Buy and raises the price target from $21 to $25.

Truist证券分析师Asthika Goonewardene维持Sutro Biophma(纳斯达克:STRO)的买入,并将目标价从21美元上调至25美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发